Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34259 | 0.88 | GAA (0.48) | GAAMAPT | |
| Hydrochloric Acid SCHEMBL160640 | 0.86 | GAA (0.46) | GAAMAPT | |
| Bromide SCHEMBL10654286 | 0.86 | GAA (0.46) | GAAMAPT | |
| Water SCHEMBL4672877 | 0.86 | GAA (0.46) | GAAMAPTNPC1RAB9AHSD17B10 | |
| SCHEMBL1787947 | 0.86 | GAA (0.46) | GAAMAPT | |
| SCHEMBL8654087 | 0.86 | GAA (0.46) | GAAMAPT | |
| Water SCHEMBL16465946 | 0.86 | GAA (0.46) | GAAMAPTNPC1RAB9AHSD17B10 | |
| Iodide SCHEMBL12466756 | 0.86 | GAA (0.46) | GAAMAPT | |
| Ammonia Solution, Strong SCHEMBL4151802 | 0.86 | GAA (0.46) | GAAMAPT | |
| SCHEMBL29181632 | 0.86 | GAA (0.46) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628949-A4 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORP (US) | 2008-07-02 | — | — | EP | claimed |
| US-7368566-B2 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-06 | — | — | US | claimed |
| JP-2006522139-A | — | — | 2006-09-28 | — | — | JP | claimed |
| US-20060194786-A1 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| EP-1628949-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-01 | — | — | EP | claimed |
| WO-2004089890-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2023220526-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-1628949-A4 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORP (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7368566-B2 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060194786-A1 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| EP-1628949-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004089890-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194786-A1 | Process and intermediates for preparing benzazepines | CYP2E1, CYP1B1, CYP3A4 | CA12 4268/4885CA1 2817/4885CA2 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.